var data={"title":"Adefovir: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Adefovir: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5572?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">see &quot;Adefovir: Drug information&quot;</a> and <a href=\"topic.htm?path=adefovir-patient-drug-information\" class=\"drug drug_patient\">see &quot;Adefovir: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708606\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Severe acute exacerbations of hepatitis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe acute exacerbations of hepatitis have been reported in patients who have discontinued anti&ndash;hepatitis B therapy, including adefovir. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who discontinue anti&ndash;hepatitis B therapy. If appropriate, resumption of anti&ndash;hepatitis B therapy may be warranted.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Nephrotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">In patients at risk of or having underlying renal dysfunction, long-term administration of adefovir may result in nephrotoxicity. Closely monitor renal function in these patients; they may require dose adjustment.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">HIV resistance:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">HIV resistance may emerge in chronic hepatitis B patients with unrecognized or untreated HIV infection treated with anti&ndash;hepatitis B therapies that may have activity against HIV (eg, adefovir).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Lactic acidosis/severe hepatomegaly with steatosis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130623\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Hepsera</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4663221\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Hepsera</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F996369\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiretroviral Agent, Reverse Transcriptase Inhibitor (Nucleotide)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F996398\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">see &quot;Adefovir: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Hepatitis B infection, chronic: Note:</b> Optimal duration of treatment not established, continuation of therapy for at least 12 months after seroconversion has been suggested. Prolonged therapy (up to 4 years) has been reported to be safe and well-tolerated in pediatric patients (2 to 18 years). Patients not achieving a &lt;2 log decrease in serum HBV DNA after at least 6 months of therapy should either receive additional treatment or be switched to an alternative therapy (AASLD [Terrault 2016]; Jonas 2012; Lok 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to &lt;7 years: Limited data available; efficacy results variable: Oral: 0.3 mg/kg/dose once daily; maximum dose: 10 mg (Jonas 2008; Jonas 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;7 to &lt;12 years: Limited data available; efficacy results variable: Oral: 0.25 mg/kg/dose once daily; maximum dose: 10 mg (Jonas 2008; Jonas 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents: Oral: 10 mg once daily; in HIV-exposed/-positive patients not requiring combination antiretroviral therapy or receiving a lamivudine- or emtricitabine-containing HIV-suppressive regimen, adefovir may be considered as HBV alternate therapy (interferon is preferable) (HHS [pediatric 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Hepatitis B infection, chronic:</b> Oral: 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment duration (AASLD practice guidelines): Treatment duration for nucleos(t)ide analog-based therapy (eg, adefovir) is variable and influenced by HBeAg status, duration of HBV suppression, and presence of cirrhosis/decompensation (AASLD [Terrault 2016]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients <i>without</i> cirrhosis:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hepatitis B e antigen positive (HBeAg-positive) immune-active chronic hepatitis: Treat until HBeAg seroconversion; after seroconversion, prolonged duration of therapy is often required in patients treated with nucleos(t)ide anaglogues. Optimal duration is unknown; however, consolidation therapy is generally a minimum of 12 months of persistently normal ALT and undetectable serum HBV DNA levels after HBeAg seroconversion.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HBeAg-negative immune-active chronic hepatitis: Indefinite antiviral therapy is suggested unless there is competing rationale for discontinuation (risk/benefit decision); treatment discontinuation may be considered in patients with loss of HBsAg; however, there is insufficient evidence to guide decisions in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients <i>with</i> cirrhosis:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HBeAg-positive immune-active chronic hepatitis: In patients who seroconvert on therapy, continue antiviral therapy indefinitely due to concerns with decompensation and death, unless there is a strong competing rationale for discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HBeAg-negative immune-active chronic hepatitis: Treatment discontinuation is not recommended due to potential for decompensation and death (limited data).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Viral breakthrough</i> <i>(AASLD practice guidelines): </i>Patients with confirmed viral breakthrough (HBV DNA &ge;100 IU/mL with previously undetectable levels [&lt;10 IU/mL] or &gt;1 log increase in HBV DNA) should either be switched to an alternative antiviral monotherapy agent with a high genetic barrier to resistance or receive a second antiviral agent with a complementary resistance profile; consult current clinical practice guidelines for recommended agents (AASLD [Terrault 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; no data available; consider dosage reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer&rsquo;s labeling: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;50 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 30 to 49 mL/minute: 10 mg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 29 mL/minute: 10 mg every 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; no data available in nonhemodialysis patients.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: Dialyzable (~35%): 10 mg every 7 days (following dialysis)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The following guidelines have been used by some clinicians (Aronoff 2007): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;50 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 20 to 49 mL/minute: 10 mg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &le;19 mL/minute: 10 mg every 72 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130602\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as dipivoxil: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepsera: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130587\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F996404\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May be administered without regard to food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130619\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store controlled room temperature of 25&deg;C (77&deg;F); excursions permitted between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F996370\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of chronic hepatitis B with evidence of active viral replication and either persistent elevations of ALT or AST or histologically active disease (FDA approved in ages &ge;12 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130645\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Pruritus, skin rash </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hypophosphatemia (&lt;2 mg/dL in pre-/post-liver transplant patients)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, flatulence, nausea, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Hepatitis (exacerbation; within 12 weeks of adefovir discontinuation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Back pain, weakness </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Increased serum creatinine (&ge;0.5 mg/dL in compensated liver disease; incidence may be higher in patients with decompensated cirrhosis or in liver transplant recipients), renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Cough, rhinitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Fanconi's syndrome, hepatitis, myopathy, nephrotoxicity, osteomalacia, pancreatitis, proximal tubular nephropathy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130607\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to adefovir or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130591\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactic acidosis/hepatomegaly: <b>[US Boxed Warning]: Fatal cases of lactic acidosis and severe hepatomegaly with steatosis have been reported with the use of nucleoside analogues alone or in combination with other antiretrovirals;</b> use with caution in patients with risk factors for liver disease (risk may be increased with female gender, obesity, pregnancy or prolonged exposure) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic hepatitis B: <b>[US Boxed Warning]: Severe, acute exacerbation of hepatitis B may occur upon discontinuation.</b> Exacerbations may occur in up to 25% of patients and usually within 12 weeks and may be self-limited or resolve upon resuming treatment; risk may be increased with advanced liver disease or cirrhosis. Monitor liver function several months after stopping treatment; reinitiation of antihepatitis B therapy may be required. Ethanol should be avoided in hepatitis B infection due to potential hepatic toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV: <b>[US Boxed Warning]:</b> <b>May cause the development of HIV resistance in chronic hepatitis B patients with unrecognized or untreated HIV infection.</b> Determine HIV status prior to initiating treatment with adefovir.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: <b>[US Boxed Warning]: Use with caution in patients with renal dysfunction or in patients at risk of renal toxicity (including concurrent nephrotoxic agents or NSAIDs).</b> Chronic administration may result in nephrotoxicity. Dosage adjustment is required in adult patients with renal dysfunction or in patients who develop renal dysfunction during therapy; no data available for use in children &ge;12 years or adolescents with renal impairment. Calculation of creatinine clearance in all patients is recommended prior to initiating therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tenofovir: Do not use concurrently with tenofovir (Viread&reg;) or any product containing tenofovir (eg, Truvada, Atripla, Complera).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Current clinical hepatitis B practice guidelines do not recommend adefovir for initial use in the management of chronic HBV due to high rate of resistance with long-term use; other antiviral agents with a high barrier to drug resistance are preferred (eg, tenofovir or entecavir). In the setting of lamivudine-resistant HBV, adefovir (including when combined with lamivudine) is also not a preferred strategy to manage antiviral resistance; consult current clinical practice guidelines for recommendations (AASLD [Terrault 2016]). If used, combination therapy with lamivudine should be used to decrease the risk of resistance in patients with lamivudine-resistant HBV.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819723\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Efficacy in pediatric patients &lt;12 years has not been reported; in clinical trials of children 2 to 12 years, positive responses to adefovir therapy were observed (13% to 17% of subjects evaluated); however, findings did not reach statistical significance (Jonas 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298688\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OAT1, OAT3; <b>Inhibits</b> MRP2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130596\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=86241&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ataluren: May increase the serum concentration of Adefovir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: Adefovir may diminish the therapeutic effect of Tenofovir Products. Adefovir may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Adefovir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OAT3 Substrates.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130620\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Food does not have a significant effect on adefovir absorption. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130598\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130610\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll women exposed to adefovir during pregnancy in the Hepsera pregnancy registry (800-258-4263). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F996406\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">HIV status (prior to initiation of therapy); serum creatinine (prior to initiation and during therapy); LFTs for several months following discontinuation of adefovir; HBV DNA (every 3 to 6 months during therapy); HBeAg and anti-HBe; if at risk for renal impairment, also consider serum phosphate, urinalysis (glucose/protein); bone density for individuals at risk for fracture or history of osteopenia (AASLD [Terrault 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130590\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Acyclic nucleotide reverse transcriptase inhibitor (adenosine analog) which interferes with HBV viral RNA-dependent DNA polymerase resulting in inhibition of viral replication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130606\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Pharmacokinetic data reported in pediatric patients (12-18 years) similar to reported adult data.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: 0.35 to 0.39 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &le;4% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Prodrug; rapidly converted to adefovir (active metabolite) in intestine </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 59% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 7.5 hours; prolonged in renal impairment </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Median: 1.75 hours (range: 0.58 to 4 hours)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (45% as active metabolite within 24 hours); Dialysis: ~35% of dose (10 mg) removed during 4 hours hemodialysis session </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130609\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Adefovir Dipivoxil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $1,136.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Hepsera Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $1,698.01</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130612\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adepact (KR);</li>\n      <li>Adepam (KR);</li>\n      <li>Adepsera (KR);</li>\n      <li>Adeptin (KR);</li>\n      <li>Adesil (KR);</li>\n      <li>Adovir (BD);</li>\n      <li>Adsera (IN);</li>\n      <li>Afoliva (KR);</li>\n      <li>Antiva (BD);</li>\n      <li>Everhepa (KR);</li>\n      <li>Gomrusa (VN);</li>\n      <li>Hepcure (KR);</li>\n      <li>Hepovir (PK);</li>\n      <li>Hepsera (AE, AR, AT, AU, BB, BE, BG, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IS, IT, JO, KR, KW, LT, LU, LV, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, VE, VN);</li>\n      <li>Hepssel (KR);</li>\n      <li>Infovir (BD);</li>\n      <li>Rezoven (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haber BA, Block JM, Jonas MM, et al, &quot;Recommendations for Screening, Monitoring, and Referral of Pediatric Chronic Hepatitis B,&quot; <i>Pediatrics</i>, 2009, 124(5):1007-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adefovir-pediatric-drug-information/abstract-text/19805457/pubmed\" target=\"_blank\" id=\"19805457\">19805457</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. Department of Health and Human Services. December 2016. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adefovir-pediatric-drug-information/abstract-text/11705428/pubmed\" target=\"_blank\" id=\"11705428\">11705428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jonas MM, Block JM, Haber BA, et al, &quot;Treatment of Children With Chronic Hepatitis B Virus Infection in the United States: Patient Selection and Therapeutic Options,&quot; <i>Hepatology</i>, 2010, 52(6):2192-205.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adefovir-pediatric-drug-information/abstract-text/20890947/pubmed\" target=\"_blank\" id=\"20890947\">20890947</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jonas MM, Kelly D, Pollack H, et al, &quot;Safety, Efficacy, and Pharmacokinetics of Adefovir Dipivoxil in Children and Adolescents (Age 2 to &lt;18 Years) With Chronic Hepatitis B,&quot; <i>Hepatology</i>, 2008, 47(6):1863-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adefovir-pediatric-drug-information/abstract-text/18433023/pubmed\" target=\"_blank\" id=\"18433023\">18433023</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jonas MM, Kelly D, Pollack H, et al, &quot;Efficacy and Safety of Long-Term Adefovir Dipivoxil Therapy in Children With Chronic Hepatitis B Infection,&quot; <i>Pediatr Infect Dis J</i>, 2012, 31(6):578-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adefovir-pediatric-drug-information/abstract-text/22466329/pubmed\" target=\"_blank\" id=\"22466329\">22466329</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lok AS and McMahon BJ, &quot;Chronic Hepatitis B: Update 2009,&quot; <i>Hepatology</i>, 2009, 50(3):661-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adefovir-pediatric-drug-information/abstract-text/19714720/pubmed\" target=\"_blank\" id=\"19714720\">19714720</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sokal EM, Kelly D, Wirth S, et al, &quot;The Pharmacokinetics and Safety of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B Virus Infection,&quot; <i>J Clin Pharmacol</i>, 2008, 48(4):512-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adefovir-pediatric-drug-information/abstract-text/18276803/pubmed\" target=\"_blank\" id=\"18276803\">18276803</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. <i>Hepatology</i>. 2016;63(1):261-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adefovir-pediatric-drug-information/abstract-text/26566064/pubmed\" target=\"_blank\" id=\"26566064\">26566064</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 86241 Version 90.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708606\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F130623\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F4663221\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F996369\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F996398\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F130602\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F130587\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F996404\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F130619\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F996370\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F130645\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F130607\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F130591\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819723\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298688\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F130596\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F130620\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F130598\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F130610\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F996406\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F130590\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F130606\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F130609\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F130612\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/86241|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">Adefovir: Drug information</a></li><li><a href=\"topic.htm?path=adefovir-patient-drug-information\" class=\"drug drug_patient\">Adefovir: Patient drug information</a></li></ul></div></div>","javascript":null}